SBSean Boyd

Sean Boyd

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sean Boyd has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Troponin T clearance via continuous renal replacement therapies in the ICU

    by Sean Boyd, Sabina Mason, Sean Griffin, Britto Pereppadan, Stephen Moyles, Krishna Reddy, Colm Keane, Eoin Begley, Evelyn Deasy, Maria Donnelly, et al.

    The aim of this study was to compare the removal of cardiac troponin T via continuous venovenous haemofiltration (CVVH), continuous venovenous haemodialysis (CVVHD) and continuous venovenous haemodiafiltration (CVVHDF) as a function of circulating blood troponin T levels in critically ill patients. This was a single-centre, prospective observational study conducted at Tallaght University Hospital (Dublin, Ireland). Adult patients admitted to ICU and commenced on continuous renal replacement therapy (CRRT) were included. All patients required a troponin T level > 50 ng/L. All patients were required to have commenced CRRT > 4 h prior to first sample. The aim was to take three serum samples per patient every 24 h, over a total of 72 h, with simultaneous sampling of the waste effluent for troponin T. Our primary outcome measure was estimated troponin T clearance according to CRRT modality. We found no significant difference in estimated troponin T clearance according to CRRT modality (overall median troponin T clearance of 2.6 ml/kg/h). As a secondary outcome, it was noted that the percentage of troponin T clearance was statistically significantly higher for CVVH compared to CVVHD and CVVHDF (16% vs. 15% vs. 10%, respectively; p = 0.002). No significant difference in estimated troponin T clearance was found according to CRRT modality. Our results show that clearance of troponin T on CRRT is generally small across all modalities and that ongoing treatment with CRRT is unlikely to substantially impact interpretation and tracking of troponin T results in patients with concern for acute coronary syndrome.

  • Emergency anaesthesia drug preparation in Irish training hospitals; a national survey

    by Seán Boyd, Jack Collins

    Introduction Anaesthetic and intensive care (ICU) non-consultant hospital doctors (NCHDs) cover critical care areas along with theatre anaesthesia and maternity care during on call hours. NCHDs often prepare emergency drugs so that they are available for immediate use. The nature of this is not standardised nationally and may be department driven or at the discretion of the NCHD. Aims The aim of this survey was to ascertain the practice in Irish acute hospitals in relation to drug preparation, transport, storage, specific protocols, and the availability of prefilled syringes. Methods A telephone survey of each department was undertaken between 15th February to 2nd July 2024. With consent, 17 anaesthetic NCHDs were contacted to complete a phone survey. Results The rate of use of each drug was ascertained for each tier of call. The storage and transport methods were recorded. The availability of prefilled syringes at each site was ascertained. Differences were reported between model 3 and model 4 hospitals. Conclusion Guidance on essential anaesthetic drugs exists. However, we are not aware of any specific guidelines relating to drug preparation for on call service. Each hospital may provide different services and treat a different cohort of patients. Therefore, the need for standardised protocols would need to be assessed on a hospital-specific basis.

  • Open Access

    Single‐use vs. reusable flexible bronchoscopes for airway management and in critical care: a narrative review

    by Sean Boyd, Ciara J. Murphy, Lindi Snyman

    Summary: Introduction: Flexible bronchoscopes have become essential in the operating theatre environment and in critical care. This narrative review compared single‐use and reusable flexible bronchoscopes with a focus on safety, efficacy, cost‐effectiveness and environmental impact. Methods: We searched MEDLINE, Embase and PubMed databases for studies related to flexible bronchoscopes for airway management or use in critical care. Human or animal studies of any design assessing single‐use and reusable flexible bronchoscopes were included and qualitatively synthesised. We also searched manufacturer websites for relevant data. Results: We included 52 studies and data from six manufacturer websites. There was mixed evidence for safety, and data on usability also showed significant heterogeneity, with different parameters, manufacturers and models examined. Neither single‐use nor reusable flexible bronchoscopes appeared convincingly superior to the other for safety or usability. Cost analyses showed that the rate of use of flexible bronchoscopes per year, along with several other factors, affects cost‐effectiveness for each institution, though the risk of cross‐contamination is an advantage of single‐use devices. However, sufficient evidence on the rate of bronchoscopy‐induced infection in the operating theatre and critical care environment is lacking. Due to the risk of cross‐contamination, single‐use flexible bronchoscopes must be sterilised or incinerated after use, and completely recyclable single‐use models are not currently available. Conclusions: Further research is required on safety, usability and life cycle assessment in the operating theatre and critical care environment, as well as on the rate of bronchoscopy‐induced infection. Future comparative studies, including new manufacturers and designs, may lend further insights.


  • Open Access

    The Incidence of Venous Thromboembolism in Critically Ill Patients with SARS-CoV-2 Infection Compared with Critically Ill Influenza and Community-Acquired Pneumonia Patients: A Retrospective Chart Review

    by Sean Boyd, Kai Sheng Loh, Jessie Lynch, Dhari Alrashed, Saad Muzzammil, Hannah Marsh, Mustafa Masoud, Salman Bin Ihsan, Ignacio Martin-Loeches

    The rate of venous thromboembolism in COVID-19 patients has been reported to be 30% (deep vein thrombosis 20% and pulmonary embolism 18%). This has been shown to be higher in COVID-19 patients admitted to the ICU. Prophylactic anticoagulation may be sufficient at ward level, but not in intensive care. A retrospective chart review was undertaken in a large university hospital. The review included 276 patients from COVID-19 Wave 1, COVID-19 Wave 2, influenza, and community-acquired pneumonia groups. The timeframe included patients admitted between 23 February 2014 and 12 May 2021. Clinical characteristics, outcomes, blood results, rates of venous thromboembolism, and anticoagulation status were recorded. The incidence of venous thromboembolism in COVID-19 Wave 1, COVID-19 Wave 2, influenza, and community-acquired pneumonia was 10.91%, 13.69%, 13.33%, and 6.81%, respectively (p = 0.481). The incidence of pulmonary embolism was 7.27%, 10.95%, 3.33%, and 5.68%, respectively (p = 0.350). The incidence of deep vein thrombosis was 5.45%, 5.48%, 10.00%, and 1.14%, respectively (p = 0.117). Although most patients were prophylactically anticoagulated, venous thromboembolism still occurred. Venous thromboembolism remains an important differential to consider in critically ill COVID-19 patients. The current literature does not advise therapeutic anticoagulation for thromboprophylaxis in the ICU.


  • Open Access

    Elevated Rates of Ventilator-Associated Pneumonia and COVID-19 Associated Pulmonary Aspergillosis in Critically Ill Patients with SARS-CoV2 Infection in the Second Wave: A Retrospective Chart Review

    by Sean Boyd, Kai Sheng Loh, Jessie Lynch, Dhari Alrashed, Saad Muzzammil, Hannah Marsh, Mustafa Masoud, Salman Bin Ihsan, Ignacio Martin-Loeches

    Due to multiple risk factors, the rate of ventilator-associated pneumonia in critically ill COVID-19 patients has been reported in a range of 7.6% to 86%. The rate of invasive pulmonary aspergillosis in this cohort has been reported at 4% to 30%. We undertook a retrospective chart review of 276 patients who were admitted to intensive care in a large university hospital. The period studied included patients from 23 February 2014 to 12 May 2021. Four groups were collected: COVID-19 Wave 1, COVID-19 Wave 2, influenza, and community-acquired pneumonia. Clinical characteristics, outcomes, and microbiological cultures were recorded. The incidence of ventilator-associated pneumonia in COVID-19 Wave 1, COVID-19 Wave 2, influenza, and community-acquired pneumonia was 5.45%, 27.40%, 16.67%, and 3.41%, respectively (p < 0.001). The rate of invasive pulmonary aspergillosis was 0%, 9.59%, 13.33%, and 6.82%, respectively (p < 0.001). A significantly elevated rate of ventilator-associated pneumonia and invasive pulmonary aspergillosis was noted in the second wave of COVID-19 when compared to the first. This was accompanied by an increase in the mortality rate. Increased steroid use was an independent risk factor for ventilator-associated pneumonia and invasive pulmonary aspergillosis across all four groups. Despite an increased understanding of this disease, no clinical trials have shown any promising therapeutic options at present.


  • The incidence of venous thromboembolism in critically ill patients with COVID-19 compared with critically ill non-COVID patients

    by Sean Boyd, Ignacio Martin-Loeches

    Background COVID-19 is a novel coronavirus that is currently responsible for the global pandemic. It has been reported that up to 25% [1] of hospitalized patients with COVID-19 develop VTE (venous thromboembolism), and this can be as high as 31% in ICU patients with COVID-19 [2]. Aims To determine VTE rates in ICU patients with COVID compared to those admitted with influenza and a control group. Methods We performed a retrospective chart review of 113 patients admitted to ICU at our hospital. Patient characteristics, comorbidities, coagulation profile and prevalence of radiologically proven VTE were recorded and compared between groups. Results More males than females were found in each group. When groups were compared the mean age, BMI and cigarette smoking were similar, as was the incidence of diabetes, chronic obstructive pulmonary disease and chronic kidney disease. aPTT was higher in the COVID-19 (30.9 ± 3.7 SD) vs (12.8 ± 4.1 SD) the influenza group vs (15.2 ± 4.1 SD) in controls p < 0.001, but fibrinogen was lower 6.2 ± 1.6 SD vs 34.6 ± 14.0SD vs 30.8 ± 5.0 SD, respectively, p < 0.001. VTE rates in the COVID (13.2%) (DVT 5.3%, PE 10.5%) and influenza groups (15.8%) (DVT 13.2%, PE 2.6%) were similar but were higher than the control group (8.1%) (DVT 8.1%, PE 2.7%), but not significantly so (p = 0.5). Conclusions ICU patients with COVID-19 displayed an abnormal coagulation profile and a VTE rate that is similar to ICU patients with influenza. VTE occurred despite thromboprophylaxis and remains a pertinent differential to keep in mind.


  • Analgesia, anaesthesia and obstetric outcome in women with inherited bleeding disorders

    by Sean C. Boyd, Anna D. O’cOnnor, Maebh A. Horan, Pat Dicker, Catherine Manning, C. Lynch, C. Regan, K. Ryan, T. Tan, B.M. Byrne